Zopiclone is a prescription Z-drug used for short-term insomnia. It can impair alertness the next day and cause dependence or withdrawal. It does not replace assessment of why sleep is disturbed. NHS: zopiclone. Confidence: high for medicine identity and urgent safety boundaries; moderate for attributed care guidance; low for a financially cleared comparative benefit estimate.
- Suspected overdose needs emergency help immediately; do not wait for symptoms. MHRA: Z-drug patient resource.
- Stopping an established prescription requires an individual plan. NICE NG215: withdrawal care.
- CBT-I is the guideline’s first-line approach to chronic adult insomnia. European insomnia guideline 2023.
- Do not add a sleep supplement without checking interactions. NCCIH: supplement safety.
Table of contents
- Evidence summary
- What zopiclone is: Zimovane, tablet prescriptions and short-term insomnia
- How it works: sedation, GABA signalling and next-day function
- Evidence-based care: CBT-I, short prescribing courses and planned review
- Supplements and daily support: no established replacement or safe sleep stack
- What benefit is established: short-term reports, conflicts and long-term gaps
- Side effects and urgent care: driving, overdose and complex sleep behaviour
- Interactions: alcohol, opioids, other sedatives and CYP3A4-altering medicines
- Who needs extra assessment: breathing disease, pregnancy and breastfeeding
- Clinician-led use and stopping: missed doses, dependence and flexible withdrawal
- Animal and laboratory evidence: mechanisms cannot establish human dependence risk
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Adult insomnia | UK clinical/product context | Public and maker sources separated | Short prescribed use; no personal dose. |
| CBT-I | Attributed 2023 adult guideline | Dated lead ties and COI access gap | First-line pathway, no product ranking. |
| Comparative drug benefit | 2022 review abstract/declarations | Connected authors; trial chain unclosed | No independent efficacy estimate. |
| Dependence and stopping | 2026 safety review and care guidance | Industry-fee regulator disclosed | Individual plan, not a forced rapid taper. |
| Suspected overdose | Actual Z-drug emergency leaflet | MHRA financial route stated | Immediate emergency help; NHS distinction retained. |
| Breastfeeding | Leaflet and limited SPS assessment | Maker/public context, trials unclosed | Selected infant scope; specialist decision. |
What zopiclone is: Zimovane, tablet prescriptions and short-term insomnia
Zimovane contains zopiclone for adult insomnia. Its leaflet limits the usual course to four weeks including tapering. Follow the actual dispensed product, not another person’s prescription. Zimovane: patient leaflet.
England’s 2025/26 community table records 4,088,705 zopiclone prescription items. Repeat items are included. This describes prescribing activity, not the number of patients, worldwide popularity, safe long-term use or clinical benefit. NHSBSA: zopiclone item count.
The PCA dataset covers NHS community-dispensed items in England, with defined exclusions; it is not a complete record of hospital use or all private prescribing. A prescription-frequency comparison must keep its geography, period and counting unit attached. NHSBSA: item-count methods.
Check the name and active ingredient on the packet. A familiar brand name, another person’s previous prescription or a high prescribing count does not answer whether this medicine is appropriate for your current sleep problem. The prescriber needs to consider the diagnosis and the plan after the short course.
How it works: sedation, GABA signalling and next-day function
NICE’s dated technologies chapter describes Z-drugs as chemically distinct from benzodiazepines but acting at the GABA receptor complex. Sedation does not establish restored daytime function, freedom from dependence or long-term treatment of the cause of insomnia. NICE TA77: drug mechanisms.
Pain, anxiety, depression, shift work, stimulants and medicines can disturb sleep. Restless legs, snoring with breathing pauses and other sleep disorders can require a different assessment. Tell the clinician about daytime problems as well as the time spent awake. Persistent or disabling insomnia merits review rather than repeated self-treatment. NHS: insomnia assessment.
Loud snoring, gasping or observed pauses in breathing with daytime tiredness can suggest sleep apnoea. Assessment may involve overnight tests. Sleeping pills can worsen the condition and should not be used without a doctor’s recommendation. A sedative is not a substitute for investigating abnormal breathing. NHS: sleep apnoea assessment.
For review, distinguish difficulty getting to sleep from repeated waking, early waking and feeling unrefreshed. Include what changed when treatment began and what a partner or caregiver noticed. The useful question is whether daily functioning and safety improved enough to justify the actual burdens.
Evidence-based care: CBT-I, short prescribing courses and planned review
The 2023 European guideline recommends CBT-I first for chronic adult insomnia, including comorbid illness. It can be delivered in person or digitally. Medicines may be considered when it is insufficient, through shared assessment. This is attributed care guidance with disclosed financial limits, not a conflict-cleared ranking of drugs or digital products. European insomnia guideline 2023.
NICE’s 2004 appraisal recommends considering non-drug measures first and limiting hypnotics to short licensed use for severe insomnia interfering with everyday life. Its selection framework did not identify compelling evidence distinguishing certain hypnotics. That dated recommendation is not a modern superiority trial or an instruction to switch medicines yourself. NICE TA77: short-term hypnotics.
The Scottish prescribing guide emphasizes assessment, discussion of expectations and planned follow-up. Psychological support, guided self-help and suitable community support may be considered according to the problem, preferences and available practitioners. More complex mental health or substance-use presentations can need specialist care; do not assume that a basic sleep leaflet is sufficient. Scotland: care recommendations.
Ask whether the aim is temporary relief while another problem is treated, or treatment of ongoing insomnia. Ask who will review the prescription, what benefit they will assess and how CBT-I can be accessed. A digital treatment should be considered on its own evidence and suitability, rather than chosen only because it is described as CBT.
Supplements and daily support: no established replacement or safe sleep stack
NCCIH describes inconsistent insomnia findings for valerian and uncertainty about longer-term safety. Kava has been linked to serious liver injury. These sources do not establish a supplement that treats the cause of insomnia, replaces clinical care or prevents Z-drug withdrawal. Their underlying studies and reviewer interests are not financially cleared here. NCCIH: sleep and complementary approaches.
Give the pharmacist the full ingredients of any supplement or herbal sleep remedy. Safety varies with other medicines, pregnancy and health conditions. Natural marketing language does not establish compatibility with a prescription sedative; disclose products already used before adding another. NCCIH: supplement safety.
Falls assessment includes medicines, balance, eyesight and home hazards. Discuss nighttime bathroom trips, stairs, poor lighting and whether somebody needs help moving safely. After a fall, inability to get up or suspected head, neck, back or hip injury requires emergency help. Do not dismiss an injury as an ordinary sleeping-pill effect. NHS: falls and medicine review.
Prepare questions about routines, practical help and treatment access. A simpler medicine list and clear instructions can make review easier, but organizational support does not make a harmful combination safe. Do not use an unverified supplement or somebody else’s medicine as a bridge when the prescribed effect seems weaker.
What benefit is established: short-term reports, conflicts and long-term gaps
The 2022 review reports short-term improvement versus placebo and more adverse-effect discontinuation with zopiclone. However, its publicly funded review has commercially connected authors, and the full underlying-trial funding appendix was not obtained. These outcomes are attributed context, not an independently established product verdict. Short-term comparisons do not establish durable benefit from years of nightly use. De Crescenzo: 2022 insomnia review.
MHRA’s 2026 assessment examined communication of dependence, addiction, tolerance and withdrawal. It considered licence-holder submissions, reporting, prescribing data and stakeholder accounts. Efficacy, dose and indications were outside its scope. A warning update therefore does not measure sleep benefit or compare zopiclone with another hypnotic. MHRA: 2026 warning review.
Pharmaceutical companies draft labels, regulators approve them and companies publish them on eMC. Pharmaceutical subscriptions pay for that channel. Approved prescribing information serves a safety and licensing role; it does not become independent product-outcome research through approval or publication. eMC: publishing and payment process.
The independent efficacy question remains narrower than the prescribing question. An unclear financial chain does not prove an outcome false, but it limits the verdict that can be made under this site’s conflict screen. No numerical benefit estimate or independently established superiority over another sleeping medicine is supplied.
Side effects and urgent care: driving, overdose and complex sleep behaviour
Common effects include bitter taste, dry mouth and next-day tiredness. The UK NHS advice is no driving, cycling or machinery for 12 hours after a dose, and longer while sleepy or less alert. It separately advises NHS 111 after taking more than prescribed; do not drive to hospital. NHS: zopiclone.
MHRA’s January 2026 Z-drug resource gives stronger advice for suspected overdose: call 999 immediately if you think someone has taken too much. Outside the UK, use the local emergency number. Do not wait for severe symptoms. This differs from the NHS extra-dose wording above; suspected overdose or uncertainty about serious harm needs immediate help. MHRA: Z-drug patient resource.
Sudden lip, mouth, tongue or throat swelling, trouble swallowing or breathing can signal a serious allergic reaction. Call 999 immediately in the UK, or the local emergency number elsewhere. This requires immediate hospital assessment, even without a rash. NHS: anaphylaxis emergency.
Unresponsiveness, a seizure or severe breathing difficulty requires emergency action. Follow the dispatcher’s instructions; do not induce vomiting, give food or drink, or attempt a home antidote. Keep the medicine packaging for responders. NHS: poisoning emergency.
If you cannot keep yourself or somebody else safe, or serious self-injury or overdose has occurred, seek emergency assistance immediately. The NHS distinguishes that immediate danger from other urgent mental-health concerns, for which it offers 111 or an urgent GP appointment. Outside the UK, use local urgent and emergency services. NHS: mental health emergencies.
Sleepwalking, driving, eating or sex while not fully awake can occur after the first or a later dose. The label directs immediate discontinuation and medical contact after complex sleep behaviour. This serious-reaction exception differs from routine withdrawal of an established prescription. Zimovane: SmPC.
Report new confusion, hallucinations, unusual behaviour or troublesome sedation promptly. Severe symptoms take priority over a routine medicines enquiry. Give responders accurate information about what was taken, when and which other substances may be involved; do not delay help while trying to establish an exact amount.
Interactions: alcohol, opioids, other sedatives and CYP3A4-altering medicines
Alcohol and other sedatives can increase impairment; opioid combinations can suppress breathing and cause coma or death. Clarithromycin, certain antifungals and ritonavir can increase exposure; rifampicin, some anticonvulsants and St John’s wort can reduce it. These are examples, not a complete interaction list or a dose-adjustment plan. Zimovane: SmPC.
The Scottish guide prioritizes review for people taking opioids, gabapentinoids or other psychotropic medicines alongside benzodiazepines or Z-drugs. Frailty, cognitive problems, falls, multiple medicines and recent hospital discharge also matter. The combined medicine burden can be more important than whether each individual prescription appears ordinary. Scotland: priority medicine review.
Tell every prescriber and pharmacist about zopiclone before starting another medicine or undergoing a procedure. Use exact active ingredients for cough medicines, pain relief, antihistamines and nonprescription sleep aids. Do not adjust the prescription to compensate for an interaction; ask the clinician to assess the complete list.
Who needs extra assessment: breathing disease, pregnancy and breastfeeding
The reviewed leaflet prohibits use with sleep apnoea, respiratory failure, severe liver problems, myasthenia gravis or a previous complex sleep behaviour after Zimovane. Pregnancy is not recommended; late exposure can affect the newborn. Discuss these circumstances and any pregnancy plans before treatment. Its breastfeeding advice is to avoid use. Zimovane: patient leaflet.
SPS permits selected short-term zopiclone use during breastfeeding with infant monitoring, but only for healthy full-term infants and with very limited evidence. It advises avoiding bedsharing after sedating medicines. Premature or unwell infants, several medicines or feeding/breathing concerns require specialist assessment. This differs from the product leaflet; neither source establishes blanket safety. SPS: insomnia during breastfeeding.
Do not choose between the leaflet and a specialist recommendation on your own. Tell the team the infant’s age and health, all medicines and the reason treatment is being considered. An individualized prescribing assessment is needed; this guide provides no safe pregnancy dose, milk threshold or infant-monitoring timetable.
Clinician-led use and stopping: missed doses, dependence and flexible withdrawal
Follow the dispensing instructions: bedtime use, no repeat dose that night and no doubling a missed dose. The short-course limit includes tapering; established withdrawal can take longer. It is not a rapid-reduction deadline. Zimovane: patient leaflet.
The January 2026 warning stresses that dependence and withdrawal can occur even during short use at recommended doses. Physical dependence is not identical to addiction. Discuss a stopping strategy before treatment begins; if the effect weakens, contact the prescriber instead of increasing the dose or adding a top-up sedative. MHRA: January 2026 warning.
NICE recommends an agreed review and gradual, adaptable withdrawal. New symptoms can reflect withdrawal, the original problem or another illness. The clinician may adjust the plan when symptoms are intolerable. Do not independently stop an established prescription abruptly, copy a published taper or substitute another hypnotic. NICE NG215: withdrawal care.
Scotland’s guide describes negotiated reduction and frequent support. Switching to diazepam is a possible clinical approach rather than an automatic requirement; equivalence tables are approximate and response differs. Review readiness, previous difficulties and the setting needed for support. No personal conversion, reduction percentage or timetable is supplied here. Scotland: reducing and stopping.
A structured review asks what matters to the person, whether the medicine is still needed, whether goals are being reached and which adverse effects have occurred. Discuss sedation, memory, falls, supply and the ability to follow the plan. Continuing, changing or reducing treatment requires a shared decision, not an automatic repeat prescription. Scotland: person-centred review.
Animal and laboratory evidence: mechanisms cannot establish human dependence risk
A laboratory signal, drug concentration, feeling sleepy and safe daytime functioning are different outcomes. Animal models cannot establish a human dose, guarantee freedom from dependence or settle the safety of a long prescribing course. This guide does not supply animal-derived treatment instructions.
When a claim is based on a mechanism or an early experiment, ask what human outcome was measured and whether the population and duration match the proposed use. Also ask whether commercial sponsorship was checked. Stronger biological explanations do not remove the need to measure benefit, harm and long-term uncertainty.
Funding and source roles
Research funding at a glance
39 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| MHRA: January 2026 warning | Own agency accounts below. Adviser contracts and source-specific allocations unclosed; review included licence-holder data. | UK; MHRA, London | Tier 3 — industry-fee regulator; safety context | C provisional. 8 January 2026. Public safety mandate; fees do not prove a particular finding is biased. |
| MHRA: 2026 warning review | Same agency route; assessed licence-holder submissions as well as reporting/patient data. Specific payments unclosed. | UK; MHRA, London | Tier 3 — industry-fee regulator; review context | C provisional. 8 January 2026. Public safety mandate; fees do not prove a particular finding is biased. |
| NICE NG215: withdrawal care | See NICE accounts/membership below; committee interests and underlying trials unclosed. | England; NICE, Manchester/London | Tier 2 — public care guidance; provisional | C provisional. Published 20 April 2022; later MHRA link is not a new guideline date. |
| NHS: insomnia assessment | Dated national policy below; exact page, contributor and trial finances unclosed. | England, UK; national website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 19 March 2024. Public-service incentives; no cleared drug outcome. |
| NHS: poisoning emergency | Dated national policy below; exact page, contributor and trial finances unclosed. | England, UK; national website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 12 June 2025. Public-service incentives; no cleared drug outcome. |
| NHS: falls and medicine review | Dated national policy below; exact page, contributor and trial finances unclosed. | England, UK; national website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 6 March 2025. Public-service incentives; no cleared drug outcome. |
| NHS: sleep apnoea assessment | Dated national policy below; exact page, contributor and trial finances unclosed. | England, UK; national website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 11 May 2026. Public-service incentives; no cleared drug outcome. |
| NCCIH: sleep and complementary approaches | Dated fiscal route below. Credited NCCIH reviewers’ outside interests and original-study finances unclosed. | United States; Bethesda, Maryland | Tier 2 — public safety/uncertainty context | C provisional. May 2024. Public education; no independent product efficacy adopted. |
| NCCIH: supplement safety | See dated fiscal row; page/expert and original-study finance unclosed. | United States; Bethesda, Maryland | Tier 2 — public safety context; provisional | C provisional. Footer January 2019 despite later references; date limit retained. |
| NHS national website content policy | Dated DHSC website funding; no ads/corporate sponsorship stated. Individual provider finances and current contracts unclosed. | England, United Kingdom; national website jurisdiction | Tier 3 — institutional financial/process self-report | B provisional process self-report. Reviewed 14 October 2022; October 2025 review due has passed. |
| NCCIH FY 2025 congressional justification | NIH/HHS federal budget route; historical request, not current enactment. Gifts/page allocation unclosed. | United States; NCCIH, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional historical self-report. Page says it no longer reflects current HHS policy; budget-advocacy incentives. |
| MHRA: 2025/26 audited accounts | Industry statutory fees and nonstatutory customer charges, plus DHSC grant-in-aid. Licence/vigilance fees document an industry relationship; warning/adviser allocation unknown. | UK; 10 South Colonnade, London | Tier 3 — institutional financial self-report | B provisional financial facts. Published 15 July 2026; selected audited notes, not full backer clearance. |
| NICE: 2025/26 accounts | DHSC/NHS England support plus appraisal/advice fees and other income. Specific TA77/NG215 allocations and committee contracts unclosed. | UK; Manchester/London | Tier 3 — institutional financial self-report | B provisional statutory financial facts. 2025/26 selected note6 read; does not clear the 2004 or 2022 committees. |
| NICE NG215: membership | NICE-appointed group; Margaret Lally chaired from January 2021, Cathy Stannard topic adviser. Named affiliations do not disclose payments. | UK; guideline committee | Tier 3 — institutional process self-report | B provisional membership facts. Full interests/contracts and original-trial funds remain unclosed. |
| Scotland: working group | Government group chaired by Alastair Cook; deputy Alpana Mair. Provider/charity participation; individual contracts and trial sponsors unclosed. | Scotland, UK; Edinburgh | Tier 3 — institutional process self-report | B provisional identities. 14 August 2024; membership is not a financial declaration. |
| Scotland: public financial framework | Block grant, taxes and permitted borrowing public routes; exact prescribing-guide allocation unknown. | Scotland, UK; government jurisdiction | Tier 3 — institutional financial/process self-report | B provisional selected framework. Fiscal index does not clear NHS bodies or working-group interests. |
| Scotland: government identity | Government contact self-report; financial framework separate. Individual contributors not cleared. | UK; St Andrew’s House, Regent Road, Edinburgh | Tier 3 — institutional identity self-report | B provisional location facts. Updated 7 October 2024; service incentives. |
| SPS: own commissioning disclosure | NHS England commissioning of provider-trust contracts/subcontracts. Stated contracts end 31 March 2026; subsequent renewal and page allocation unverified. | England, UK; multiprovider network | Tier 3 — institutional funding/process self-report | B provisional dated disclosure. Current October 2026 arrangements and contributors’ interests unknown. |
| eMC: publishing and payment process | Datapharm owns/manages eMC; pharma subscriptions pay for publishing. Companies draft/publish regulator-approved labels; complete ultimate-owner chain unclosed. | UK; Cassini Court, Randalls Way, Leatherhead | Tier 4 — paid maker publishing channel | B provisional process facts; D for independent efficacy. Paid-publication incentives persist after regulatory review. |
| NHSBSA: item-count methods | Authority finance below; exact PCA allocation, contributor and capture-chain interests unclosed. | England data; UK authority, Newcastle upon Tyne | Tier 3 — institutional method self-report | B provisional. June 2026 release; reimbursement records do not measure treatment benefit. |
| NHSBSA: zopiclone item count | Authority finance below; exact PCA allocation, contributor and capture-chain interests unclosed. | England data; UK authority, Newcastle upon Tyne | Tier 2 — public statistics; provisional | B provisional. June 2026 release; reimbursement records do not measure treatment benefit. |
| NHSBSA: 2025/26 publication | Authority finance below; exact PCA allocation, contributor and capture-chain interests unclosed. | England data; UK authority, Newcastle upon Tyne | Tier 2 — public statistics; provisional | B provisional. June 2026 release; reimbursement records do not measure treatment benefit. |
| NHSBSA: 2025/26 audited institutional accounts | DHSC sponsor/appointed board; main Parliamentary support plus full-cost service-contract income and public repayment work. Separate student-support routes. Specific PCA allocation and staff/contractor interests unknown. | United Kingdom; Stella House, Goldcrest Way, Newcastle upon Tyne | Tier 3 — institutional financial/identity self-report | B provisional. Report printed 13 July 2026. Accountability/service incentives; selected notes read, complete subsidiary/backer audit unclosed. |
| NHS: zopiclone | Dated national website policy below; page, contributor and trial finances unclosed. | England, UK; national website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 22 June 2026. Public education, not independently cleared drug efficacy. |
| NHS: anaphylaxis emergency | Dated national policy below; page, contributor and supporting-source finance unclosed. | England, UK; national website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 21 June 2023; June 2026 review due passed. Emergency education, not product efficacy. |
| NHS: mental health emergencies | National policy below; exact page and contributor finances unclosed. | England, UK; national website | Tier 2 — public clinical context; provisional | C provisional. Reviewed 26 April 2023; April 2026 review due date passed. |
| Zimovane: SmPC | Sanofi/Aventis Pharma licence holder, Reading, UK. Maker sales; eMC paid channel below. Ultimate owners/product receipts unclosed. | UK licence; Sanofi, Reading | Tier 4 — maker-produced; self-interest | D for independent efficacy. Text 11 February 2026; posted 18 February 2026. |
| Zimovane: patient leaflet | Sanofi holder, Reading; lists Sanofi Winthrop industrie, Tours, France, as manufacturer. Product-specific, not every generic factory. | UK licence; French listed manufacturer | Tier 4 — maker-produced; self-interest | D for independent efficacy. Six-page original footer November 2025; eMC posting 7 April 2026. |
| MHRA: Z-drug patient resource | Agency financial route below; specific adviser/page allocations unclosed. | UK; MHRA, London | Tier 3 — industry-fee regulator; safety context | C provisional. January 2026 resource. Safety mandate; fees do not prove capture. |
| SPS: insomnia during breastfeeding | Own commissioning disclosure below; page reviewers and original evidence finances unclosed. | England, UK; provider network | Tier 2 — public clinical context; provisional | C provisional. Published 8 March 2024. Very limited evidence; healthy full-term infants only. |
| Scotland: care recommendations | Government framework/group below; contributor contracts and original-trial finances unclosed. | Scotland, UK; Edinburgh | Tier 2 — public clinical context; provisional | C provisional. 14 August 2024. Public care context; no independent drug ranking. |
| Scotland: priority medicine review | Government framework/group below; contributor contracts and original-trial finances unclosed. | Scotland, UK; Edinburgh | Tier 2 — public clinical context; provisional | C provisional. 14 August 2024. Public care context; no independent drug ranking. |
| Scotland: person-centred review | Government framework/group below; contributor contracts and original-trial finances unclosed. | Scotland, UK; Edinburgh | Tier 2 — public clinical context; provisional | C provisional. 14 August 2024. Public care context; no independent drug ranking. |
| Scotland: reducing and stopping | Government framework/group below; contributor contracts and original-trial finances unclosed. | Scotland, UK; Edinburgh | Tier 2 — public clinical context; provisional | C provisional. 14 August 2024. Public care context; no independent drug ranking. |
| NICE TA77: short-term hypnotics | Own accounts below. Historic committee/source finance unclosed; current fees do not prove 2004 sponsorship. | England; NICE, Manchester/London | Tier 2 — public clinical context; provisional | C provisional. 28 April 2004. Dated appraisal framework; not current comparative efficacy clearance. |
| NICE TA77: drug mechanisms | Same institutional route; 2004 committee and underlying source finances unclosed. | England; NICE, Manchester/London | Tier 2 — public clinical context; provisional | C provisional. 28 April 2004. Dated descriptive context; no independent benefit claim. |
| De Crescenzo: 2022 insomnia review | Review: NIHR Oxford Health BRC. Authors disclose Boehringer employment, Angelini fees and Janssen depression-trial leadership. Current payments/underlying sponsors unclosed. | UK-led; Oxford, multinational authors | Tier 3 — commercially connected authors | C. 2022 original abstract/full declaration read; public review funding does not clear authors or trials. |
| European insomnia guideline 2023 | Original: ESRS €1,000 proofreading, no other financial support; Projekt DEAL open access. Dated lead declaration below; 2023 COI PDF 403. | European network; lead Freiburg, Germany; society HQ unclosed | Tier 3 — dated connected lead; context | C provisional. 28 November 2023. Graded consensus; current contracts and underlying-trial funds unclosed. |
| Riemann: 2026 declared interests | 9 April 2026 original: lead Riemann discloses Idorsia/Heel speaking and consultancy, plus digital-therapy firms. Not proof of 2023 or page payment. | Germany; corresponding author Freiburg | Tier 3 — commercial author interests | C for connected-source provenance. Actual declaration/affiliations read; subscription clinical body not used. |
Frequently asked questions
Is zopiclone for long-term self-treatment? No. It is used for short-term insomnia; arrange review rather than extending it yourself. NHS: zopiclone.
What should I do after suspected zopiclone overdose? Seek emergency help immediately. Do not wait for symptoms or attempt a home antidote. MHRA: Z-drug patient resource.
Can I stop zopiclone suddenly? An established prescription needs an individual withdrawal plan; do not copy a taper or stop abruptly yourself. NICE NG215: withdrawal care.
What if I sleepwalk or drive while not fully awake? Stop taking it and contact the clinician immediately, as the label directs for complex sleep behaviour. Zimovane: SmPC.
Is zopiclone automatically safe while breastfeeding? No. The limited specialist context applies to healthy full-term infants and requires individual assessment. SPS: insomnia during breastfeeding.
Is public review funding proof of independent efficacy? No. Author interests and the original trials must also be checked; this review is commercially connected context. De Crescenzo: 2022 insomnia review.
Sources and funding notes
Reviewed 4 October 2026. UK product examples do not close worldwide licensing, generic formulations or every interaction. Manufacturer labels and the paid publishing channel are Tier 4/D for independent outcomes. MHRA’s documented fee route is separate from its statutory safety mandate and is not proof of capture. Its warning review excluded efficacy. The 2023 guideline’s original funding is distinguished from a later 2026 author declaration; historic payments and complete author forms remain unclosed. Public institutional funding and membership do not clear page contributors or underlying trials. NHS extra-dose advice and MHRA suspected-overdose instructions are identified separately. Leaflet text, posting and professional-label dates differ. No personal dose, forced taper, drug-conversion schedule or supplement replacement is supplied. Whole-source budgets include complete linked nodes, profiles/references and reserves for all repeated evidence/notes/metadata facts.
- MHRA: January 2026 warning — Dependence, tolerance and individual withdrawal care.
- MHRA: 2026 warning review — Warning-method scope, not efficacy reassessment.
- NICE NG215: withdrawal care — Shared review, symptom assessment and adaptable withdrawal.
- NHS: insomnia assessment — Underlying causes and CBT context; no comparative efficacy estimate.
- NHS: poisoning emergency — Emergency response; never induce vomiting.
- NHS: falls and medicine review — Falls assessment, home hazards and urgent injury care.
- NHS: sleep apnoea assessment — Breathing symptoms, testing and sleeping-pill caution.
- NCCIH: sleep and complementary approaches — Valerian uncertainty, kava hazard and no substitute claim.
- NCCIH: supplement safety — Full ingredient disclosure and interaction uncertainty.
- NHS national website content policy — National website policy, not provider or trial finance.
- NCCIH FY 2025 congressional justification — Institutional route only; no present appropriation or product efficacy.
- MHRA: 2025/26 audited accounts — Agency finance only; no maker sponsorship of a specific conclusion inferred.
- NICE: 2025/26 accounts — Institutional income only; guideline/trial interests separate.
- NICE NG215: membership — NG215 committee identities only.
- Scotland: working group — Named guideline contributors; no financial clearance.
- Scotland: public financial framework — Government finance context only.
- Scotland: government identity — Publisher location, not study-country proof.
- SPS: own commissioning disclosure — SPS-specific route; national NHS website policy not substituted.
- eMC: publishing and payment process — Label provenance only, not neutral trial evidence.
- NHSBSA: item-count methods — Community versus hospital scope and item definition.
- NHSBSA: zopiclone item count — England community prescription items, not patients or benefit.
- NHSBSA: 2025/26 publication — Date and scope, not worldwide popularity.
- NHSBSA: 2025/26 audited institutional accounts — Institutional finance only; no drug efficacy, item accuracy or maker influence inferred.
- NHS: zopiclone — Common effects, driving, missed dose and NHS extra-dose advice.
- NHS: anaphylaxis emergency — Serious allergy signs and immediate emergency action.
- NHS: mental health emergencies — Immediate danger versus urgent mental-health assessment.
- Zimovane: SmPC — Mechanism, interactions and serious behaviour warning.
- Zimovane: patient leaflet — Contraindications, course/handling and pregnancy caution.
- MHRA: Z-drug patient resource — Overdose emergency and dependence distinction.
- SPS: insomnia during breastfeeding — Specialist assessment, infant monitoring and no bedsharing.
- Scotland: care recommendations — Non-drug support and planned follow-up.
- Scotland: priority medicine review — Frailty, falls and sedative combinations.
- Scotland: person-centred review — Goals, actual benefit, adverse effects and shared decisions.
- Scotland: reducing and stopping — Flexible reduction; switching is not automatic.
- NICE TA77: short-term hypnotics — Short prescribing course and attributed selection framework.
- NICE TA77: drug mechanisms — GABA mechanism and chemically distinct Z-drug class.
- De Crescenzo: 2022 insomnia review — Attributed short-term findings only; no independent efficacy verdict.
- European insomnia guideline 2023 — Attributed adult CBT-I pathway; no drug superiority claim.
- Riemann: 2026 declared interests — Dated author relationship only.
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
